Click to enlarge
Diabetic Cardiovascular Blood Vessels, Repairing Vascularendothelial Tissue and Improving Cardiovascular
Guangdong, ChinaFoshan Biophilia Tech Co., Ltd.
US$1699.00
Lead Time
| Quantity | 旺季 | 淡季 |
|---|---|---|
| 1 - 2 | 6 days | 6 days |
| > 2 | To be negotiated | To be negotiated |
Product profile
- Function
- Control blood sugar, Diabetic neuropathy ,Diabetic nephropathy,
- Voltage
- 100V-130V/200V-240V 50-60Hz
- Place of Origin
- Guangdong, China
- Item Form
- Tape
- Model Number
- BHA-315
- Product name
- DIABETES THERAPEUTIC APPARATUS
- Brand Name
- OEM
- Max. Capacity
- 1L
- Single package size
- 46X36X31.5 cm
- Shelf Life
- 1years
- Service
- Online Technical Support
- product benefits
- Moisturizing, detox, Firming, Hypoallergenic, Eye Care, oxygenating, PAIN RELIEF, anti itch, Hair Growth, anti fungal, headache relief, Anti aging, sleep support
- Quality Certification
- CE
- Main Ingredient
- Vitamin E, Vitamin C, Chamomile, Charcoal, PEPTIDE, Lavender, Ginseng, Silicon, Orange, Vitamin B, Honey, Vitamin A, Resveratrol
- Application
- Personal Care
- Function 2
- Diabetic foot,cerebrovascular diseases
- Single gross weight
- 7.200 kg
- Warranty
- 1 Year
- Feature
- Eye complications ,Diabetic cardiovascular,
- Color
- White
- Certificate
- CE ISO
- Selling Units
- Single item
Company profile
Foshan Biophilia Tech Co., Ltd.
广东百菲亚科技有限公司Guangdong, China116th, Building 12, Hong'an Garden, No. 23 Xiqing Avenue, Southwest Street Foshan Guangdong China- CertifiedTrade Assurance
- Business Type: Manufacturer, Distributor/Wholesaler
- Established: 2021
- Plant Area: 1,000-3,000 square meters
- Annual Export Value: US$1 Million - US$2.5 Million
- Avg. Response Time: ≤ 3h
Main Products
- biophilia tracker
- meta hunter 4025
- 9d nls
- bioplasm nls
- laser pain relief machine
Main Markets
Southern Europe(50.0%), Eastern Europe(50.0%), Oceania(50.0%), Western Europe(50.0%), South America(40.0%), Central America(40.0%), Southeast Asia(30.0%), South Asia(30.0%), Domestic Market(30.0%), North America(30.0%), Eastern Asia(30.0%), Mid East(30.0%), Northern Europe(25.0%), Africa(20.0%)
